—ARIKAYCE® (amikacin liposome
inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding
the Upper End of Guidance Range with Unaudited Global Net Product
Sales of Approximately $305.2
Million—
—2024 Global ARIKAYCE Revenues Expected to be
Between $340 Million and $360 Million, Reflecting Double-Digit Growth
Compared to 2023—
—Topline Data from the Phase 3 ASPEN Study of
Brensocatib in Adult Patients with Bronchiectasis Remains on Track
to Read Out in the Latter Part of Second-Quarter 2024—
—Enrollment in the Phase 2 Study of TPIP in
Patients with PH-ILD Completed in November
2023; Topline Data Expected in Second-Quarter 2024—
BRIDGEWATER, N.J., Jan. 5, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global
biopharmaceutical company on a mission to transform the lives of
patients with serious and rare diseases, today provided an update
on the Company's four pillars and outlook for 2024. These updates
will be discussed as part of the Company's presentation at the
42nd Annual J.P. Morgan Healthcare Conference in
San Francisco on Monday, January 8, 2024, at 3:00 p.m. PT (6:00 p.m.
ET).
"The year ahead will mark the most transformational period in
Insmed's history as we strive to become the next great
biotechnology company," said Will
Lewis, Chair and Chief Executive Officer of Insmed. "From
the readout of our highly anticipated Phase 3 ASPEN study, to our
first Phase 2 topline TPIP data, to the advancement of our ARIKAYCE
label expansion program, 2024 is the moment we have been waiting
for. Each of these three programs, if successful, has the potential
to achieve peak sales of more than $1
billion. Over the next 12 months, we have the opportunity to
truly break out from the pack, delivering tangible results for our
shareholders, while, more importantly, making a meaningful impact
in the lives of patients with serious and rare diseases."
Preliminary Full Year 2023 Global Net Product Sales
(Unaudited)
Based on preliminary unaudited financial information, the
Company expects total global net product sales of ARIKAYCE to be
approximately $305.2 million for the
full year 2023, with net sales across the
United States, Japan, and
Europe as follows. This represents
24% year-over-year growth from the full year 2022, including growth
in the U.S. of 21% and in Japan of
16%.
Preliminary
Unaudited Full Year 2023 Global Net Product Sales by
Region
|
United
States
|
$224.2
million
|
Japan
|
$65.7
million
|
Europe
|
$15.3
million
|
Total
|
$305.2
million
|
These preliminary unaudited results are subject to
adjustment. Insmed will report its final and complete
fourth-quarter and full-year 2022 financial results in late
February 2024, and the actual results
could be materially different from these preliminary unaudited
financial results.
Progress and Anticipated Milestones by Pillar:
Pillar 1: ARIKAYCE
- Insmed anticipates 2024 global ARIKAYCE revenues to be between
$340 million and $360 million, representing 15% year-over-year
growth at the midpoint compared to 2023.
- The Company has completed its original target enrollment of 250
patients in the ENCORE trial in patients with newly diagnosed or
recurrent nontuberculous mycobacterial lung infection caused by
Mycobacterium avium complex (MAC) who had not started
antibiotics. Enrollment in the study remains ongoing.
- Insmed received encouraging written feedback from the U.S. Food
and Drug Administration (FDA) on the patient-reported outcome data
produced in the Phase 3 ARISE study in December 2023. As expected, the Company will seek
a meeting with the Agency in the coming months to gain additional
insights and guidance, from which it will finalize its statistical
plans for the Phase 3 ENCORE study, including an updated enrollment
target for the study.
- The Company continues to anticipate a topline readout for
ENCORE in 2025.
Pillar 2: Brensocatib
- Insmed expects topline data from the Phase 3 ASPEN study of
brensocatib in adult patients with non-cystic fibrosis
bronchiectasis in the latter part of the second quarter of 2024. If
successful, the Company anticipates a launch in the U.S. in
mid-2025, followed by launches in Europe and Japan in the first half of 2026.
- The Data Safety Monitoring Committee for the ASPEN study held its fifth and final meeting
in November 2023. No new safety
signals were identified, and the Committee unanimously recommended
that the trial continue as planned.
- Insmed anticipates providing topline data from the Phase
2b BiRCh trial of brensocatib in
patients with chronic rhinosinusitis without nasal polyps (CRSsNP)
in 2025.
- The Company expects to initiate a Phase 2 study of brensocatib
in patients with hidradenitis suppurativa (HS) in the second
half of 2024.
Pillar 3: TPIP
- Insmed has completed enrollment in the Phase 2 study of
treprostinil palmitil inhalation powder (TPIP) in pulmonary
hypertension associated with interstitial lung disease (PH-ILD).
The Company exceeded its enrollment target of 32 patients, with 39
patients enrolled. Topline data from the study are anticipated
ahead of Phase 3 ASPEN data in the second quarter of 2024.
- Enrollment in the Phase 2 study of TPIP in pulmonary arterial
hypertension (PAH) remains ongoing. The Company anticipates
enrolling 99 patients in the study, 45 of whom had been enrolled by
year-end 2023, with topline results expected in 2025.
Pillar 4: Early-Stage Research
- Insmed's early-stage research efforts include more than 30
identified pre-clinical programs in development, all of which have
the potential to become first-in-class or best-in-class
therapies.
- The Company continues to anticipate that the totality of its
early-stage research programs will comprise less than 20% of
overall spend.
Presentation at the 42nd Annual J.P. Morgan
Healthcare Conference
Will Lewis, Chair and Chief
Executive Officer of Insmed, will present at the 42nd
Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT (6:00 p.m.
ET). A live audio webcast of the presentation will be
available on the Investor Relations section of the Company's
website at www.insmed.com. A replay will also be archived
for a period of 30 days following the conclusion of the live
event.
About ARIKAYCE
ARIKAYCE is approved in the United
States as ARIKAYCE® (amikacin liposome inhalation
suspension), in Europe as
ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion, and in
Japan as ARIKAYCE®
inhalation 590 mg (amikacin sulfate inhalation drug product).
Current international treatment guidelines recommend the use of
ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled,
once-daily formulation of amikacin, an established antibiotic that
was historically administered intravenously and associated with
severe toxicity to hearing, balance, and kidney function. Insmed's
proprietary PULMOVANCE® liposomal technology enables the
delivery of amikacin directly to the lungs, where liposomal
amikacin is taken up by lung macrophages where the infection
resides, while limiting systemic exposure. ARIKAYCE is administered
once daily using the Lamira® Nebulizer System
manufactured by PARI Pharma GmbH (PARI).
About PARI Pharma and the Lamira® Nebulizer
System
ARIKAYCE is delivered by a novel inhalation device, the
Lamira® Nebulizer System, developed by PARI.
Lamira® is a quiet, portable nebulizer that enables
efficient aerosolization of ARIKAYCE via a vibrating, perforated
membrane. Based on PARI's 100-year history working with aerosols,
PARI is dedicated to advancing inhalation therapies by developing
innovative delivery platforms to improve patient care.
About Brensocatib
Brensocatib is a small molecule, oral, reversible inhibitor of
dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the
treatment of patients with bronchiectasis and other
neutrophil-mediated diseases. DPP1 is an enzyme responsible for
activating neutrophil serine proteases (NSPs), such as neutrophil
elastase, in neutrophils when they are formed in the bone marrow.
Neutrophils are the most common type of white blood cell and play
an essential role in pathogen destruction and inflammatory
mediation. In chronic inflammatory lung diseases, neutrophils
accumulate in the airways and result in excessive active NSPs that
cause lung destruction and inflammation. Brensocatib may decrease
the damaging effects of inflammatory diseases such as
bronchiectasis by inhibiting DPP1 and its activation of NSPs.
Brensocatib is an investigational drug product that has not been
approved for any indication in any jurisdiction.
About TPIP
Treprostinil palmitil inhalation powder (TPIP) is a dry powder
formulation of treprostinil palmitil, a treprostinil prodrug
consisting of treprostinil linked by an ester bond to a 16-carbon
chain. Developed entirely in Insmed's laboratories, TPIP is a
potentially highly differentiated prostanoid being evaluated for
the treatment of patients with PAH, PH-ILD, and other rare and
serious pulmonary disorders. TPIP is administered in a
capsule-based inhalation device. TPIP is an investigational drug
product that has not been approved for any indication in any
jurisdiction.
IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.
WARNING: RISK OF
INCREASED RESPIRATORY ADVERSE REACTIONS
ARIKAYCE has been associated with an increased risk of respiratory
adverse reactions, including hypersensitivity pneumonitis,
hemoptysis, bronchospasm, and exacerbation of underlying pulmonary
disease that have led to hospitalizations in some
cases.
|
Hypersensitivity Pneumonitis has been reported with the
use of ARIKAYCE in the clinical trials. Hypersensitivity
pneumonitis (reported as allergic alveolitis, pneumonitis,
interstitial lung disease, allergic reaction to ARIKAYCE) was
reported at a higher frequency in patients treated with ARIKAYCE
plus background regimen (3.1%) compared to patients treated with a
background regimen alone (0%). Most patients with hypersensitivity
pneumonitis discontinued treatment with ARIKAYCE and received
treatment with corticosteroids. If hypersensitivity pneumonitis
occurs, discontinue ARIKAYCE and manage patients as medically
appropriate.
Hemoptysis has been reported with the use of ARIKAYCE in
the clinical trials. Hemoptysis was reported at a higher frequency
in patients treated with ARIKAYCE plus background regimen (17.9%)
compared to patients treated with a background regimen alone
(12.5%). If hemoptysis occurs, manage patients as medically
appropriate.
Bronchospasm has been reported with the use of ARIKAYCE
in the clinical trials. Bronchospasm (reported as asthma, bronchial
hyperreactivity, bronchospasm, dyspnea, dyspnea exertional,
prolonged expiration, throat tightness, wheezing) was reported at a
higher frequency in patients treated with ARIKAYCE plus background
regimen (28.7%) compared to patients treated with a background
regimen alone (10.7%). If bronchospasm occurs during the use of
ARIKAYCE, treat patients as medically appropriate.
Exacerbations of underlying pulmonary disease has been
reported with the use of ARIKAYCE in the clinical trials.
Exacerbations of underlying pulmonary disease (reported as chronic
obstructive pulmonary disease (COPD), infective exacerbation of
COPD, infective exacerbation of bronchiectasis) have been reported
at a higher frequency in patients treated with ARIKAYCE plus
background regimen (14.8%) compared to patients treated with
background regimen alone (9.8%). If exacerbations of underlying
pulmonary disease occur during the use of ARIKAYCE, treat patients
as medically appropriate.
Anaphylaxis and Hypersensitivity Reactions: Serious and
potentially life-threatening hypersensitivity reactions, including
anaphylaxis, have been reported in patients taking ARIKAYCE. Signs
and symptoms include acute onset of skin and mucosal tissue
hypersensitivity reactions (hives, itching, flushing, swollen
lips/tongue/uvula), respiratory difficulty (shortness of breath,
wheezing, stridor, cough), gastrointestinal symptoms (nausea,
vomiting, diarrhea, crampy abdominal pain), and cardiovascular
signs and symptoms of anaphylaxis (tachycardia, low blood pressure,
syncope, incontinence, dizziness). Before therapy with ARIKAYCE is
instituted, evaluate for previous hypersensitivity reactions to
aminoglycosides. If anaphylaxis or a hypersensitivity reaction
occurs, discontinue ARIKAYCE and institute appropriate supportive
measures.
Ototoxicity has been reported with the use of ARIKAYCE in
the clinical trials. Ototoxicity (including deafness, dizziness,
presyncope, tinnitus, and vertigo) were reported with a higher
frequency in patients treated with ARIKAYCE plus background regimen
(17%) compared to patients treated with background regimen alone
(9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE
plus background regimen vs 0.9% in the background regimen alone
arm) and dizziness (6.3% in ARIKAYCE plus background regimen vs
2.7% in the background regimen alone arm). Closely monitor patients
with known or suspected auditory or vestibular dysfunction during
treatment with ARIKAYCE. If ototoxicity occurs, manage patients as
medically appropriate, including potentially discontinuing
ARIKAYCE.
Nephrotoxicity was observed during the clinical trials of
ARIKAYCE in patients with MAC lung disease but not at a higher
frequency than background regimen alone. Nephrotoxicity has been
associated with the aminoglycosides. Close monitoring of patients
with known or suspected renal dysfunction may be needed when
prescribing ARIKAYCE.
Neuromuscular Blockade: Patients with neuromuscular
disorders were not enrolled in ARIKAYCE clinical trials. Patients
with known or suspected neuromuscular disorders, such as myasthenia
gravis, should be closely monitored since aminoglycosides may
aggravate muscle weakness by blocking the release of acetylcholine
at neuromuscular junctions.
Embryo-Fetal Toxicity: Aminoglycosides can cause fetal
harm when administered to a pregnant woman. Aminoglycosides,
including ARIKAYCE, may be associated with total, irreversible,
bilateral congenital deafness in pediatric patients exposed in
utero. Patients who use ARIKAYCE during pregnancy, or become
pregnant while taking ARIKAYCE should be apprised of the potential
hazard to the fetus.
Contraindications: ARIKAYCE is contraindicated in
patients with known hypersensitivity to any aminoglycoside.
Most Common Adverse Reactions: The most common adverse
reactions in Trial 1 at an incidence ≥5% for patients using
ARIKAYCE plus background regimen compared to patients treated with
background regimen alone were dysphonia (47% vs 1%), cough (39% vs
17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%),
ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%),
musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs
10%), exacerbation of underlying pulmonary disease (15% vs 10%),
diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%),
headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash
(6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs
1%), and chest discomfort (5% vs 3%).
Drug Interactions: Avoid concomitant use of ARIKAYCE with
medications associated with neurotoxicity, nephrotoxicity, and
ototoxicity. Some diuretics can enhance aminoglycoside toxicity by
altering aminoglycoside concentrations in serum and tissue. Avoid
concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea,
or intravenous mannitol.
Overdosage: Adverse reactions specifically associated
with overdose of ARIKAYCE have not been identified. Acute toxicity
should be treated with immediate withdrawal of ARIKAYCE, and
baseline tests of renal function should be undertaken. Hemodialysis
may be helpful in removing amikacin from the body. In all cases of
suspected overdosage, physicians should contact the Regional Poison
Control Center for information about effective treatment.
U.S. INDICATION
LIMITED POPULATION: ARIKAYCE® is indicated in adults,
who have limited or no alternative treatment options, for the
treatment of Mycobacterium avium complex (MAC) lung disease
as part of a combination antibacterial drug regimen in patients who
do not achieve negative sputum cultures after a minimum of 6
consecutive months of a multidrug background regimen therapy. As
only limited clinical safety and effectiveness data for ARIKAYCE
are currently available, reserve ARIKAYCE for use in adults who
have limited or no alternative treatment options. This drug is
indicated for use in a limited and specific population of
patients.
This indication is approved under accelerated approval based
on achieving sputum culture conversion (defined as 3 consecutive
negative monthly sputum cultures) by Month 6. Clinical benefit has
not yet been established. Continued approval for this indication
may be contingent upon verification and description of clinical
benefit in confirmatory trials.
Limitation of Use: ARIKAYCE has only been studied in
patients with refractory MAC lung disease defined as patients who
did not achieve negative sputum cultures after a minimum of 6
consecutive months of a multidrug background regimen therapy. The
use of ARIKAYCE is not recommended for patients with non-refractory
MAC lung disease.
Patients are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1‑800‑FDA‑1088. You can also call the Company at
1-844-4-INSMED.
Please see Full Prescribing Information.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United
States, Europe, and
Japan to treat a chronic,
debilitating lung disease. The Company is progressing a robust
pipeline of investigational therapies targeting areas of serious
unmet need, including neutrophil-mediated inflammatory diseases and
rare pulmonary disorders. Insmed is also advancing an early-stage
research engine encompassing a wide range of technologies and
modalities, including artificial intelligence-driven protein
engineering, gene therapy, and protein manufacturing. Insmed is
headquartered in Bridgewater, New
Jersey, with additional offices and research locations
throughout the United States,
Europe, and Japan. Visit www.insmed.com to learn more.
Forward-looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. "Forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995, are statements that are not
historical facts and involve a number of risks and uncertainties.
Words herein such as "may," "will," "should," "could," "would,"
"expects," "plans," "anticipates," "believes," "estimates,"
"projects," "predicts," "intends," "potential," "continues," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) may
identify forward-looking statements.
The forward-looking statements in this press release are based
upon the Company's current expectations and beliefs, and involve
known and unknown risks, uncertainties and other factors, which may
cause the Company's actual results, performance and achievements
and the timing of certain events to differ materially from the
results, performance, achievements or timings discussed, projected,
anticipated or indicated in any forward-looking statements. Such
risks, uncertainties and other factors include, among others, the
following: failure to obtain, or delays in obtaining, regulatory
approvals for ARIKAYCE outside the U.S., Europe or Japan, or for the Company's product candidates
in the U.S., Europe, Japan or other markets, including separate
regulatory approval for the Lamira® Nebulizer System in
each market and for each usage; failure to successfully
commercialize ARIKAYCE, the Company's only approved product, in the
U.S., Europe or Japan (amikacin liposome inhalation
suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin
sulfate inhalation drug product, respectively), or to maintain
U.S., European or Japanese approval for ARIKAYCE, or failure to
successfully commercialize any of the Company's product candidates
in the future; business or economic disruptions due to catastrophes
or other events, including natural disasters or public health
crises; impact of the COVID-19 pandemic and efforts to reduce its
spread on the Company's business, employees, including key
personnel, patients, partners and suppliers; risk that brensocatib
or TPIP does not prove to be effective or safe for patients in
ongoing and future clinical studies, including, for brensocatib,
the ASPEN study; uncertainties in
the degree of market acceptance of ARIKAYCE by physicians,
patients, third-party payors and others in the healthcare
community; the Company's inability to obtain full approval of
ARIKAYCE from the FDA, including the risk that the Company will not
successfully or in a timely manner validate a PRO tool and complete
the confirmatory post-marketing clinical trial required for full
approval of ARIKAYCE; inability of the Company, PARI or the
Company's other third-party manufacturers to comply with regulatory
requirements related to ARIKAYCE or the Lamira®
Nebulizer System; the Company's inability to obtain adequate
reimbursement from government or third-party payors for ARIKAYCE or
acceptable prices for ARIKAYCE or for the Company's other product
candidates; development of unexpected safety or efficacy concerns
related to ARIKAYCE, brensocatib, TPIP or the Company's other
product candidates; inaccuracies in the Company's estimates of the
size of the potential markets for ARIKAYCE, brensocatib, TPIP or
the Company's other product candidates or in data the Company has
used to identify physicians, expected rates of patient uptake,
duration of expected treatment, or expected patient adherence or
discontinuation rates; the risks and uncertainties associated with,
and the perceived benefits of, the Company's secured senior loan
with certain funds managed by Pharmakon Advisors, LP and the
Company's royalty financing with OrbiMed Royalty & Credit
Opportunities IV, LP, including the Company's ability to maintain
compliance with the covenants in the agreements for the senior
secured loan and royalty financing and the perceived impact of the
restrictions on the Company's operations under these agreements;
the Company's inability to create an effective direct sales and
marketing infrastructure or to partner with third parties that
offer such an infrastructure for distribution of ARIKAYCE or any of
the Company's product candidates that are approved in the future;
failure to obtain regulatory approval to expand ARIKAYCE's
indication to a broader patient population; risk that the Company's
competitors may obtain orphan drug exclusivity for a product that
is essentially the same as a product the Company is developing for
a particular indication; failure to successfully predict the time
and cost of development, regulatory approval and commercialization
for novel gene therapy products; failure to successfully conduct
future clinical trials for ARIKAYCE, brensocatib, TPIP and the
Company's other product candidates due to the Company's limited
experience in conducting preclinical development activities and
clinical trials necessary for regulatory approval and its potential
inability to enroll or retain sufficient patients to conduct and
complete the trials or generate data necessary for regulatory
approval, among other things; risks that the Company's clinical
studies will be delayed, that serious side effects will be
identified during drug development, or that any protocol amendments
submitted will be rejected; risks that interim or partial data sets
are not representative of a complete or larger data set or that
blinded data will not be predictive of unblinded data; failure of
third parties on which the Company is dependent to manufacture
sufficient quantities of ARIKAYCE or the Company's product
candidates for commercial or clinical needs, to conduct the
Company's clinical trials, or to comply with the Company's
agreements or laws and regulations that impact the Company's
business or agreements with the Company; the Company's inability to
attract and retain key personnel or to effectively manage the
Company's growth; the Company's inability to successfully integrate
its recent acquisitions and appropriately manage the amount of
management's time and attention devoted to integration activities;
risks that the Company's acquired technologies, products and
product candidates are not commercially successful; the Company's
inability to adapt to its highly competitive and changing
environment; risk that the Company is unable to maintain its
significant customers; risk that government healthcare reform
materially increases the Company's costs and damages its financial
condition; deterioration in general economic conditions in the
U.S., Europe, Japan and globally, including the effect of
prolonged periods of inflation, affecting the Company, its
suppliers, third-party service providers and potential partners;
the Company's inability to adequately protect its intellectual
property rights or prevent disclosure of its trade secrets and
other proprietary information and costs associated with litigation
or other proceedings related to such matters; restrictions or other
obligations imposed on the Company by agreements related to
ARIKAYCE or the Company's product candidates, including its license
agreements with PARI and AstraZeneca AB, and failure of the Company
to comply with its obligations under such agreements; the cost and
potential reputational damage resulting from litigation to which
the Company is or may become a party, including product liability
claims; risk that the Company's operations are subject to a
material disruption in the event of a cybersecurity attack or
issue; the Company's limited experience operating internationally;
changes in laws and regulations applicable to the Company's
business, including any pricing reform, and failure to comply with
such laws and regulations; the Company's history of operating
losses, and the possibility that the Company may never achieve or
maintain profitability; goodwill impairment charges affecting the
Company's results of operations and financial condition; inability
to repay the Company's existing indebtedness and uncertainties with
respect to the Company's ability to access future capital; and
delays in the execution of plans to build out an additional
third-party manufacturing facility approved by the appropriate
regulatory authorities and unexpected expenses associated with
those plans.
The Company may not actually achieve the results, plans,
intentions or expectations indicated by the Company's
forward-looking statements because, by their nature,
forward-looking statements involve risks and uncertainties because
they relate to events and depend on circumstances that may or may
not occur in the future. For additional information about the risks
and uncertainties that may affect the Company's business, please
see the factors discussed in Item 1A, "Risk Factors," in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2022 and any subsequent
Company filings with the Securities and Exchange Commission
(SEC).
The Company cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date of
this press release. The Company disclaims any obligation, except as
specifically required by law and the rules of the SEC, to publicly
update or revise any such statements to reflect any change in
expectations or in events, conditions or circumstances on which any
such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-provides-business-update-at-42nd-annual-jp-morgan-healthcare-conference-302026833.html
SOURCE Insmed Incorporated